CN101077346A - N-取代的靛红衍生物在制备抗肿瘤药物中的应用 - Google Patents
N-取代的靛红衍生物在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN101077346A CN101077346A CN 200610081547 CN200610081547A CN101077346A CN 101077346 A CN101077346 A CN 101077346A CN 200610081547 CN200610081547 CN 200610081547 CN 200610081547 A CN200610081547 A CN 200610081547A CN 101077346 A CN101077346 A CN 101077346A
- Authority
- CN
- China
- Prior art keywords
- application
- human
- hct
- hela
- cancer cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及N-取代的靛红衍生物在制备抗肿瘤药物中的应用。所述的N-取代的靛红衍生物是N-烷基或氯烷基取代的靛红衍生物,其可以杀伤人结肠癌细胞HCT-8、人宫颈癌细胞Hela、人肺癌细胞A549、和人皮肤癌细胞A431,尤其对人皮肤癌细胞细胞有很好的杀伤能力,可应用于制备抗肿瘤药物。与现有的抗肿瘤药物相比,本发明首次发现N-烷基或氯烷基取代的靛红衍生物能够杀伤肿瘤细胞。做为天然活性物质靛红的新型衍生物,这类化合物具有原料易得、合成简便、易于工业化生产等突出优点,在抗肿瘤药物的开发应用方面具有广阔的应用前景。
Description
技术领域
本发明属于药物领域,具体地说是涉及一类N-烷基或氯烷基取代的靛红衍生物在制备抗肿瘤药物中的应用。
背景技术
目前治疗癌症的传统方法是化学药物治疗,其中很多药物是通过抑制DNA合成来阻止癌细胞生长,这些药物不仅对癌细胞有杀伤力,对正常细胞也有同样的杀伤作用。而且,这些药物通常具有很大的毒副作用,经常还会加大病人的痛苦。因此,研究新的抗癌途径,寻找合成简便,毒副作用小,耐药性高的抗癌药物已经成为当今药物研究的热点。
靛红又名吲哚醌(isatin),系海洋天然生物活性物质,是维持龙虾生存的物质,也是著名中药青黛中的有效成分。
发明内容
本发明的目的在于提供N-取代的靛红衍生物在制备抗肿瘤药物中的应用。
本发明所述的N-取代的靛红衍生物是N-烷基或氯烷基取代的靛红衍生物,其结构式如1~19所示,其合成方法如文献1:Synthesis,2002,(1),34-38和文献2:Synthesis,2001,(6),904-908中所述。
本发明所述的N-烷基或氯烷基取代的靛红衍生物具有抑制肿瘤活性,可以杀伤人结肠癌细胞HCT-8、人宫颈癌细胞Hela、人肺癌细胞A549、和人皮肤癌细胞A431,尤其对人皮肤癌细胞细胞有很好的杀伤能力,可应用于制备抗肿瘤药物。
与现有的抗肿瘤药物相比,本发明首次发现N-烷基或氯烷基取代的靛红衍生物能够杀伤肿瘤细胞。做为天然活性物质靛红的新型衍生物,这类化合物具有原料易得、合成简便、易于工业化生产等突出优点,在抗肿瘤药物的开发应用方面具有广阔的应用前景。
具体实施方式
实施例1、使用MTT方法检测N-烷基或氯烷基取代的靛红衍生物抑制HCT-8、Hela、A549和A431细胞生长的实验
将HCT-8(人结肠癌细胞),Hela(人宫颈癌细胞),A549(人肺癌细胞),A431(人皮肤癌细胞)使用含10%热灭活胎牛血清与50单位/mL青霉素和链霉素的RPMI1640生长液,在37℃,5%CO2培养箱中培养。依照文献3:J.Immunol.Methods,1983,65(1-2),55-63中的方法使用MTT法测定N-烷基或氯烷基取代的靛红衍生物(结构式1~19)的细胞毒性。取指数生长期的细胞以每孔1200~1500细胞,100μl/孔铺96孔培养板中,所测试化合物24小时后以0.5~50μg/mL的浓度加入,每个浓度做复孔。以紫杉醇做为阳性对照,细胞在37℃孵育72小时,加入浓度为0.5mg/mL的MTT100μL,继续培养4小时后加入100μL DMSO溶解生成的formazan固体。在570nm波长下分析不同浓度的化合物物对细胞的生长抑制情况。N-烷基或氯烷基取代的靛红衍生物抗肿瘤活性测试结果列于表1,表中,HCT-8为人结肠癌细胞,Hela为人宫颈癌细胞,A549为人肺癌细胞,A431为人皮肤癌细胞。
表1 N-烷基或氯烷基取代的靛红衍生物抗肿瘤活性测试结果
化合物编号 | 分子量 | 癌细胞类型 | 抑制率% | IC50(μg/mL) | IC50(μMol/L) | ||
0.5μg/mL | 5.0μg/mL | 50μg/mL | |||||
1 | 175.1840 | HCT-8 | 17.5 | 78.4 | 90.5 | 1.47 | 8.39 |
Hela | 5.9 | 58.2 | 94.6 | 3.999 | 22.83 | ||
A549 | 8.8 | 14.6 | 76.0 | 17.66 | 100.8 | ||
A431 | 71.9 | 91.4 | 92.1 | 0.125 | 0.714 | ||
2 | 191.1834 | HCT-8 | 3.4 | 32.9 | 88.9 | 8.836 | 46.22 |
Hela | 0.7 | 17.2 | 95.2 | 10.58 | 55.34 | ||
A549 | -1.6 | 6.9 | 79.2 | 21.23 | 111.05 | ||
A431 | 2.9 | 63.5 | 65.5 | 1.513 | 7.91 | ||
3 | 179.1479 | HCT-8 | 3.7 | 38.1 | 84.7 | 7.92 | 44.21 |
Hela | 1.1 | 45.3 | 95.6 | 5.494 | 30.67 | ||
A549 | -0.7 | 13.4 | 96.9 | 10.13 | 56.55 | ||
A431 | 0.9 | 65.1 | 58.6 | 1.271 | 7.09 | ||
4 | 195.6022 | HCT-8 | 7.9 | 80.4 | 98.7 | 2.103 | 10.75 |
Hela | 3.0 | 74.6 | 98.8 | 2.776 | 14.19 | ||
A549 | 0.1 | 38.9 | 98.2 | 5.971 | 30.53 | ||
A431 | 48.7 | 72.2 | 78.6 | 0.2501 | 1.28 | ||
5 | 240.0535 | HCT-8 | 7.1 | 65.0 | 94.3 | 3.026 | 12.61 |
Hela | -18.5 | 64.9 | 88.6 | 4.526 | 18.85 | ||
A549 | -3.3 | 21.1 | 98.1 | 7.273 | 30.30 | ||
A431 | 12.6 | 66.1 | 70.9 | 1.124 | 4.68 | ||
6 | 211.2161 | HCT-8 | 6.2 | 11.3 | 84.6 | 18.79 | 88.96 |
Hela | 7.0 | 71.0 | 91.4 | 2.458 | 11.64 | ||
A549 | 8.5 | 11.4 | 83.9 | 19.23 | 91.04 | ||
A431 | 14.0 | 55.6 | 65.7 | 1.476 | 6.99 |
7 | 251.7085 | HCT-8 | 8.8 | 52.2 | 98.8 | 4.675 | 18.57 |
Hela | -8.9 | 60.8 | 91.7 | 4.676 | 18.58 | ||
A549 | 6.5 | 16.4 | 97.5 | 9.803 | 38.95 | ||
A431 | 41.5 | 73.0 | 77.4 | 0.3913 | 1.55 | ||
8 | 267.7079 | HCT-8 | 8.7 | 61.3 | 98.3 | 3.462 | 12.93 |
Hela | -11.1 | 68.7 | 95.1 | 4.572 | 17.08 | ||
A549 | 2.3 | 18.7 | 86.2 | 13.48 | 50.35 | ||
A431 | 4.0 | 65.7 | 75.2 | 1.599 | 5.97 | ||
9 | 255.6724 | HCT-8 | 5.6 | 23.6 | 88.2 | 11.99 | 46.90 |
Hela | 14.7 | 24.2 | 91.4 | 11.99 | 46.90 | ||
A549 | 0.1 | 7.3 | 77.3 | 22.54 | 88.15 | ||
A431 | 8.8 | 70.1 | 75.8 | 1.185 | 4.63 | ||
10 | 272.1267 | HCT-8 | 10.5 | 48.5 | 98.9 | 5.297 | 19.47 |
Hela | 1.4 | 50.7 | 98.2 | 4.853 | 17.83 | ||
A549 | 5.4 | 9.9 | 98.5 | 9.257 | 34.02 | ||
A431 | 25.5 | 73.4 | 77.8 | 0.6887 | 2.53 | ||
11 | 316.5780 | HCT-8 | 14.1 | 76.3 | 98.9 | 2.001 | 6.32 |
Hela | 10.4 | 71.6 | 98.4 | 2.436 | 7.69 | ||
A549 | 6.6 | 30.8 | 97.4 | 7.788 | 24.6 | ||
A431 | 26.4 | 73.8 | 75.6 | 0.641 | 2.02 | ||
12 | 265.7351 | HCT-8 | 5.7 | 34.3 | 98.4 | 7.038 | 26.49 |
Hela | 1.5 | 48.8 | 98.0 | 5.061 | 19.05 | ||
A549 | 7.8 | 21.7 | 98.0 | 8.479 | 31.91 | ||
A431 | 39.0 | 89.6 | 91.8 | 0.485 | 1.83 | ||
13 | 281.7345 | HCT-8 | 8.2 | 42.7 | 98.1 | 6.246 | 22.17 |
Hela | 4.6 | 72.1 | 98.4 | 3.391 | 12.04 | ||
A549 | 1.5 | 18.9 | 97.9 | 8.219 | 29.17 | ||
A431 | 39.1 | 89.6 | 92.5 | 0.4851 | 1.72 |
14 | 286.1533 | HCT-8 | 7.8 | 61.9 | 97.9 | 3.436 | 12.01 |
Hela | -1.6 | 76.6 | 98.5 | 4.54 | 15.87 | ||
A549 | -7.3 | 24.5 | 98.2 | 5.384 | 18.82 | ||
A431 | 38.4 | 89.6 | 92.0 | 0.4915 | 1.72 | ||
15 | 267.7079 | HCT-8 | 2.2 | 36.8 | 83.9 | 8.234 | 30.75 |
Hela | -13.1 | 44.7 | 87.3 | 4.985 | 18.62 | ||
A549 | -0.5 | 8.2 | 78.2 | 19.88 | 74.26 | ||
A431 | 26.7 | 87.4 | 90.3 | 0.6372 | 2.38 | ||
16 | 283.7073 | HCT-8 | 7.3 | 58.4 | 80.1 | 3.4 | 11.98 |
Hela | -5.9 | 58.3 | 93.6 | 4.658 | 16.42 | ||
A549 | -10.1 | -1.2 | 88.8 | 17.55 | 61.86 | ||
A431 | 30.6 | 88.1 | 91.6 | 0.5886 | 2.07 | ||
17 | 279.7617 | HCT-8 | 6.7 | 46.4 | 98.8 | 5.583 | 19.96 |
Hela | -1.9 | 68.1 | 97.8 | 4.638 | 16.58 | ||
A549 | 0.7 | 19.3 | 97.4 | 8.494 | 30.36 | ||
A431 | 59.0 | 90.4 | 93.6 | 0.276 | 0.987 | ||
18 | 295.7611 | HCT-8 | 3.8 | 25.7 | 98.5 | 7.561 | 25.56 |
Hela | -14.2 | 30.0 | 97.1 | 5.422 | 18.33 | ||
A549 | 0.4 | 17.7 | 97.5 | 8.638 | 29.21 | ||
A431 | 24.2 | 89.2 | 92.4 | 0.6647 | 2.25 | ||
19 | 300.1798 | HCT-8 | 4.6 | 65.9 | 98.7 | 3.296 | 10.98 |
Hela | 7.3 | 75.6 | 96.3 | 2.693 | 8.97 | ||
A549 | -12.2 | 24.2 | 97.0 | 5.922 | 19.73 | ||
A431 | 74.8 | 90.9 | 93.1 | 0.1247 | 0.415 |
由此结果表明,N-烷基或氯烷基取代的靛红衍生物能够抑制人结肠癌细胞、人宫颈癌细胞、人肺癌细胞、和人皮肤癌细胞的增殖,特别是能够高效地抑制人皮肤癌细胞的生长,可应用于制备抗肿瘤药物。
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100815474A CN100569236C (zh) | 2006-05-26 | 2006-05-26 | N-取代的靛红衍生物在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100815474A CN100569236C (zh) | 2006-05-26 | 2006-05-26 | N-取代的靛红衍生物在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101077346A true CN101077346A (zh) | 2007-11-28 |
CN100569236C CN100569236C (zh) | 2009-12-16 |
Family
ID=38905118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100815474A Expired - Fee Related CN100569236C (zh) | 2006-05-26 | 2006-05-26 | N-取代的靛红衍生物在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100569236C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102140070A (zh) * | 2011-01-18 | 2011-08-03 | 浙江山峪染料化工有限公司 | 2-(羟基亚胺基)-n-乙酰苯胺母液回收利用方法 |
CN113480559A (zh) * | 2021-07-13 | 2021-10-08 | 北京大学深圳医院 | 一种高抗癌生物活性的蒿甲醚衍生物及其制备方法和应用 |
CN116621767A (zh) * | 2023-02-23 | 2023-08-22 | 中山大学 | 一种靛红衍生物及其制备方法和应用 |
CN116621767B (zh) * | 2023-02-23 | 2024-05-31 | 中山大学 | 一种靛红衍生物及其制备方法和应用 |
-
2006
- 2006-05-26 CN CNB2006100815474A patent/CN100569236C/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102140070A (zh) * | 2011-01-18 | 2011-08-03 | 浙江山峪染料化工有限公司 | 2-(羟基亚胺基)-n-乙酰苯胺母液回收利用方法 |
CN113480559A (zh) * | 2021-07-13 | 2021-10-08 | 北京大学深圳医院 | 一种高抗癌生物活性的蒿甲醚衍生物及其制备方法和应用 |
CN113480559B (zh) * | 2021-07-13 | 2022-06-03 | 北京大学深圳医院 | 一种蒿甲醚衍生物及其制备方法和应用 |
CN116621767A (zh) * | 2023-02-23 | 2023-08-22 | 中山大学 | 一种靛红衍生物及其制备方法和应用 |
CN116621767B (zh) * | 2023-02-23 | 2024-05-31 | 中山大学 | 一种靛红衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100569236C (zh) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017162108A1 (zh) | 一种柱芳烃类复合物、其制备方法、药物组合物和用途 | |
Al-Amiery et al. | Antioxidant and antimicrobial activities of novel quinazolinones | |
Liu et al. | Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1 | |
Shobana et al. | Synthesis, structural elucidation, biological, antioxidant and nuclease activities of some 5-Fluorouracil–amino acid mixed ligand complexes | |
Glamočlija et al. | Synthesis, biological evaluation and docking studies of benzoxazoles derived from thymoquinone | |
CN102659777A (zh) | 一种抗肿瘤药物 | |
Varlamova et al. | A comparative analysis of neuroprotective properties of taxifolin and its water-soluble form in ischemia of cerebral cortical cells of the mouse | |
CN101077346A (zh) | N-取代的靛红衍生物在制备抗肿瘤药物中的应用 | |
Markowska et al. | Role of Fisetin in Selected Malignant Neoplasms in Women | |
Aldayel | Potential antibacterial and antioxidant inhibitory activities of Silybum marianum mediated biosynthesised He-Ne laser | |
Alyami et al. | Retama monosperma chemical profile, green synthesis of silver nanoparticles, and antimicrobial potential: a study supported by network pharmacology and molecular docking | |
Zheng et al. | Selenious-β-lactoglobulin induces the apoptosis of human lung cancer A549 cells via an intrinsic mitochondrial pathway | |
CN103638052A (zh) | 双齿多刺蚁提取物及其制备和医药用途 | |
CN104055786B (zh) | 苜蓿酸-3-O-β-D-吡喃葡萄糖苷、苜蓿酸及其盐在制备防治肿瘤药物中的应用 | |
CN102503892A (zh) | 含钴夹心杂多酸及其合成方法和应用 | |
CN103232509A (zh) | 氟尿嘧啶类化合物、其制备方法及其应用 | |
Hossain et al. | Antineoplastic activity of N-(2-hydroxybenzylidene) 2′-hydroxyphenylimine aqua nickel (II) complex [NI (H2O) HHP] on ehrlich ascites carcinoma (EAC) in Swiss albino mice | |
CN110772572A (zh) | 一种森登-4洗剂及其制备方法 | |
Baig et al. | Anti-lung cancer properties of cyanobacterial bioactive compounds | |
CN110934881B (zh) | 礁膜寡二糖与礁膜寡二糖衍生物在抗结直肠癌中的应用 | |
CN103638055A (zh) | 拟黑多刺蚁提取物及其和抗真菌医药用途 | |
Zarewa et al. | Synthesis, Characterization, and Anticancer Activity of Phosphanegold (i) Complexes of 3-Thiosemicarbano-butan-2-one Oxime | |
CN101627989B (zh) | 一种小分子有机化合物jfd-03169在制备抗肿瘤药物中的用途 | |
CN111297870B (zh) | 硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 | |
CN109602775B (zh) | 乳苣醇提物在制备抗乳腺癌药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091216 Termination date: 20110526 |